Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers found. Common adverse side effects from the drugs included nausea, vomiting, ...

Ozempic and Wegovy are two popular injectable medications for weight loss and diabetes. But what’s the difference?

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, whether they utilize weight loss drugs or not,” IBX said in a statement.

Health experts have cited concerns about the medications' long-term impacts on eating behaviors and body image, especially given the developing nature of a teenager’s body and brain. “The advice from ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

"Because most people with obesity have elevated insulin levels, they develop insulin resistance, which contributes to weight gain. Semaglutide (or Ozempic) helps lower the levels of this fat-storing ...

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, manufactured by Novo Nordisk. Reuters Eli Lilly said Wednesday that its obesity drug Zepbound ...

which helped patients achieve 47% more relative weight loss compared to Wegovy. Zepbound is in a class of its own as the only FDA-approved dual GIP and GLP-1 receptor agonist obesity medication, and ...

There are currently three medications (GLP-1s) on the market that the FDA has specifically approved to treat obesity — Wegovy ...

which helped patients achieve 47% more relative weight loss compared to Wegovy. Zepbound is in a class of its own as the only FDA-approved dual GIP and GLP-1 receptor agonist obesity medication, and ...